{"component": "contracts", "props": {"contracts": [{"intro": "Portions of this Exhibit, indicated by the mark \u201c[***],\u201d were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant\u2019s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.", "id": "gSj3I6j50CQ", "source_url": "https://www.sec.gov/Archives/edgar/data/1527599/000119312517270395/d431294dex1014.htm", "category_name": "License Agreement", "company_name": "Synlogic, Inc.", "created": "August 28th, 2017", "published": true, "pretty": null, "uri": "/contracts/gSj3I6j50CQ", "title": "CONFIDENTIAL TREATMENT REQUESTED Boston University Massachusetts Institute of Technology Synlogic, Inc. License Agreement Effective as of October 18, 2015", "group_id": "gMsP1pUia6j", "group_samples": [{"label": "License Agreement", "uri": "/contracts/gMsP1pUia6j", "published": true}, {"label": "License Agreement (Synlogic, Inc.)", "uri": "/contracts/gSj3I6j50CQ", "published": true}], "group_size": 2, "tags": [{"name": "License Agreement", "type": "category", "uri": "/contracts/tagged/license-agreement"}, {"name": "Synlogic, Inc.", "type": "company", "uri": "/company/1527599/synlogic-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Massachusetts", "type": "jurisdiction", "uri": "/contracts/tagged/massachusetts-us"}]}, {"intro": "The purpose of this letter agreement (\u201cAgreement\u201d) is to confirm the terms of this separation of employment from Synlogic, Inc. (\u201cSynlogic\u201d or \u201cthe Company\u201d). The Severance Pay and Benefits described below are contingent on your agreement to and compliance with the provisions of this Agreement, as set forth below. This Agreement shall be effective on the day after you sign the same (the \u201cEffective Date\u201d).", "id": "hyAZ8XdgC5o", "source_url": "https://www.sec.gov/Archives/edgar/data/1527599/000095017024093282/sybx-ex10_3.htm", "category_name": "Separation Agreement", "company_name": "Synlogic, Inc.", "created": "August 8th, 2024", "published": true, "pretty": null, "uri": "/contracts/hyAZ8XdgC5o", "title": "Synlogic Operating Company, Inc. Cambridge, MA 02142", "group_id": "hyAZ8XdgC5o", "group_samples": [{"label": "Separation Agreement (Synlogic, Inc.)", "uri": "/contracts/hyAZ8XdgC5o", "published": true}, {"label": "Separation Agreement (Synlogic, Inc.)", "uri": "/contracts/iy1gn2Gjerl", "published": true}], "group_size": 2, "tags": [{"name": "Separation Agreement", "type": "category", "uri": "/contracts/tagged/separation-agreement"}, {"name": "Synlogic, Inc.", "type": "company", "uri": "/company/1527599/synlogic-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "This AMENDMENT NO. 2 to LICENSE AGREEMENT (this \u201cAmendment No. 2\u201d) is made and entered into effective as of May 11, 2015 (the \u201cAmendment No. 2 Effective Date\u201d), by and between Mirna Therapeutics, Inc., a Delaware corporation with offices at 2150 Woodward Street, Suite 100, Austin, Texas 78744 (\u201cMirnaRx\u201d), and Marina Biotech, Inc., a Delaware corporation with offices c/o Pryor Cashman LLP, 7 Times Square, New York, New York 10036 (\u201cMarina Bio\u201d).", "id": "1nG5Ye6b6Rw", "source_url": "https://www.sec.gov/Archives/edgar/data/1527599/000104746915007251/a2225898zex-10_3f.htm", "category_name": "License Agreement", "company_name": "Mirna Therapeutics, Inc.", "created": "September 11th, 2015", "published": true, "pretty": null, "uri": "/contracts/1nG5Ye6b6Rw", "title": "AMENDMENT No. 2 to LICENSE AGREEMENT", "group_id": "1nG5Ye6b6Rw", "group_samples": [{"label": "License Agreement (Mirna Therapeutics, Inc.)", "uri": "/contracts/1nG5Ye6b6Rw", "published": true}], "group_size": 1, "tags": [{"name": "License Agreement", "type": "category", "uri": "/contracts/tagged/license-agreement"}, {"name": "Mirna Therapeutics, Inc.", "type": "company", "uri": "/company/1527599/mirna-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "This SERVICES AGREEMENT (this \u201cAgreement\u201d) is made as of January 1, 2013 (the \u201cEffective Date\u201d) between Asuragen, Inc., a Delaware corporation (\u201cAsuragen\u201d), and Mirna Therapeutics, Inc., a Delaware corporation (\u201cMirna Therapeutics\u201d).", "id": "1waH6rvu1vK", "source_url": "https://www.sec.gov/Archives/edgar/data/1527599/000104746915006962/a2225772zex-10_1a.htm", "category_name": "Services Agreement", "company_name": "Mirna Therapeutics, Inc.", "created": "August 24th, 2015", "published": true, "pretty": null, "uri": "/contracts/1waH6rvu1vK", "title": "SERVICES AGREEMENT Between ASURAGEN, INC. and MIRNA THERAPEUTICS, INC. Dated January 1, 2013", "group_id": "1waH6rvu1vK", "group_samples": [{"label": "Services Agreement (Mirna Therapeutics, Inc.)", "uri": "/contracts/1waH6rvu1vK", "published": true}], "group_size": 1, "tags": [{"name": "Services Agreement", "type": "category", "uri": "/contracts/tagged/services-agreement"}, {"name": "Mirna Therapeutics, Inc.", "type": "company", "uri": "/company/1527599/mirna-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Texas", "type": "jurisdiction", "uri": "/contracts/tagged/texas-us"}]}, {"intro": "On behalf of Mirna Therapeutics, Inc. (\u201cMirna\u201d), a Delaware corporation, I am pleased to offer you the full-time position of Executive Vice President and Chief Scientific Officer. We anticipate your start date to be September 28, 2015 (the \u201cStart Date\u201d).", "id": "21f1E333EJN", "source_url": "https://www.sec.gov/Archives/edgar/data/1527599/000104746915007386/a2226006zex-10_22.htm", "category_name": "Employment Agreement", "company_name": "Mirna Therapeutics, Inc.", "created": "September 18th, 2015", "published": true, "pretty": null, "uri": "/contracts/21f1E333EJN", "title": "MIRNA THERAPEUTICS LOGO]", "group_id": "21f1E333EJN", "group_samples": [{"label": "Employment Agreement (Mirna Therapeutics, Inc.)", "uri": "/contracts/21f1E333EJN", "published": true}], "group_size": 1, "tags": [{"name": "Employment Agreement", "type": "category", "uri": "/contracts/tagged/employment-agreement"}, {"name": "Mirna Therapeutics, Inc.", "type": "company", "uri": "/company/1527599/mirna-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "On behalf of Mirna Therapeutics, Inc. (\u201cMirna\"), a Delaware corporation, I am pleased to offer you the full-time position of Chief Medical Officer. We anticipate your start date to be April 25, 2016 (the \u201cStart Date\u201d).", "id": "2HdcQUYfWHQ", "source_url": "https://www.sec.gov/Archives/edgar/data/1527599/000152759917000004/exhibit1026aoneillofferlet.htm", "category_name": "Employment Agreement", "company_name": "Mirna Therapeutics, Inc.", "created": "March 15th, 2017", "published": true, "pretty": null, "uri": "/contracts/2HdcQUYfWHQ", "title": "MIRNA THERAPEUTICS LETTERHEAD]", "group_id": "2HdcQUYfWHQ", "group_samples": [{"label": "Employment Agreement (Mirna Therapeutics, Inc.)", "uri": "/contracts/2HdcQUYfWHQ", "published": true}], "group_size": 1, "tags": [{"name": "Employment Agreement", "type": "category", "uri": "/contracts/tagged/employment-agreement"}, {"name": "Mirna Therapeutics, Inc.", "type": "company", "uri": "/company/1527599/mirna-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "This Agreement and Plan of Merger (this \u201cAgreement\u201d) dated as of July 16, 2015 (the \u201cExecution Date\u201d), by and among AbbVie S.\u00e0.r.l., a corporation organized under the laws of Luxembourg (\u201cBuyer\u201d), Suffolk Merger Sub, Inc. a Delaware corporation (\u201cMerger Sub\u201d), Synlogic IBDCo, Inc., a Delaware corporation (the \u201cCompany\u201d), Synlogic, LLC, a Delaware corporation (the \u201cParent\u201d), Synlogic, Inc., a wholly-owned subsidiary of the Parent (\u201cSynlogic\u201d), and (solely for purposes of Section 7.13 hereof) each of the Founders.", "id": "2qATbIdXxZS", "source_url": "https://www.sec.gov/Archives/edgar/data/1527599/000119312517270395/d431294dex1012.htm", "category_name": "Agreement and Plan of Merger", "company_name": "Synlogic, Inc.", "created": "August 28th, 2017", "published": true, "pretty": null, "uri": "/contracts/2qATbIdXxZS", "title": "CONFIDENTIAL TREATMENT REQUESTED AGREEMENT AND PLAN OF MERGER BY AND AMONG ABBVIE S.\u00c0.R.L. SUFFOLK MERGER SUB, INC. SYNLOGIC IBDCO, INC. SYNLOGIC, LLC SYNLOGIC, INC. AND THE FOUNDERS DATED AS OF JULY 16, 2015", "group_id": "2qATbIdXxZS", "group_samples": [{"label": "Agreement and Plan of Merger (Synlogic, Inc.)", "uri": "/contracts/2qATbIdXxZS", "published": true}], "group_size": 1, "tags": [{"name": "Agreement and Plan of Merger", "type": "category", "uri": "/contracts/tagged/agreement-and-plan-of-merger"}, {"name": "Synlogic, Inc.", "type": "company", "uri": "/company/1527599/synlogic-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Delaware", "type": "jurisdiction", "uri": "/contracts/tagged/delaware-us"}]}, {"intro": "This EMPLOYMENT AGREEMENT (the \u201cAgreement\u201d) is made and entered into this 22 day of May, 2013 (the \u201cEffective Date\u201d) by and between Mirna Therapeutics, Inc., a Delaware corporation (the \u201cCompany\u201d) and Sinil Kim, M.D. (\u201cEmployee\u201d).", "id": "2r1lhiAOmjR", "source_url": "https://www.sec.gov/Archives/edgar/data/1527599/000104746915007251/a2225898zex-10_17b.htm", "category_name": "Employment Agreement", "company_name": "Mirna Therapeutics, Inc.", "created": "September 11th, 2015", "published": true, "pretty": null, "uri": "/contracts/2r1lhiAOmjR", "title": "Contract", "group_id": "2r1lhiAOmjR", "group_samples": [{"label": "Employment Agreement (Mirna Therapeutics, Inc.)", "uri": "/contracts/2r1lhiAOmjR", "published": true}], "group_size": 1, "tags": [{"name": "Employment Agreement", "type": "category", "uri": "/contracts/tagged/employment-agreement"}, {"name": "Mirna Therapeutics, Inc.", "type": "company", "uri": "/company/1527599/mirna-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Texas", "type": "jurisdiction", "uri": "/contracts/tagged/texas-us"}]}, {"intro": "", "id": "3BWt6OOIzGX", "source_url": "https://www.sec.gov/Archives/edgar/data/1527599/000119312517307077/d469197dex101.htm", "category_name": "Employment Agreement", "company_name": "Synlogic, Inc.", "created": "October 10th, 2017", "published": true, "pretty": null, "uri": "/contracts/3BWt6OOIzGX", "title": "Synlogic, Inc.", "group_id": "3BWt6OOIzGX", "group_samples": [{"label": "Employment Agreement (Synlogic, Inc.)", "uri": "/contracts/3BWt6OOIzGX", "published": true}], "group_size": 1, "tags": [{"name": "Employment Agreement", "type": "category", "uri": "/contracts/tagged/employment-agreement"}, {"name": "Synlogic, Inc.", "type": "company", "uri": "/company/1527599/synlogic-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Massachusetts", "type": "jurisdiction", "uri": "/contracts/tagged/massachusetts-us"}]}, {"intro": "", "id": "3J5i5GJGMC", "source_url": "https://www.sec.gov/Archives/edgar/data/1527599/000119312517209493/d390888dex106.htm", "category_name": "Cancer Research Grant Contract", "company_name": "Mirna Therapeutics, Inc.", "created": "June 21st, 2017", "published": true, "pretty": null, "uri": "/contracts/3J5i5GJGMC", "title": "Paul Lammers, M.D., M.Sc. President and Chief Executive Officer Mirna Therapeutics, Inc.", "group_id": "3J5i5GJGMC", "group_samples": [{"label": "Cancer Research Grant Contract (Mirna Therapeutics, Inc.)", "uri": "/contracts/3J5i5GJGMC", "published": true}], "group_size": 1, "tags": [{"name": "Cancer Research Grant Contract", "type": "category", "uri": "/contracts/tagged/cancer-research-grant-contract"}, {"name": "Mirna Therapeutics, Inc.", "type": "company", "uri": "/company/1527599/mirna-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "This PATENT LICENSE AGREEMENT, effective as of December 31, 2015 (the \u201cEffective Date\u201d), is entered into between Rosetta Genomics Ltd., a corporation organized under the laws of the State of Israel, with offices at 10 Plaut Street, Science Park, Rehovot 76706, Israel (\u201cRosetta \u201d) and Mirna Therapeutics, Inc., a Texas corporation with offices at 2150 Woodward St., Suite 100, Austin, TX 78744 (\u201cMirna\u201d). Rosetta and Mirna are hereafter referred to collectively as the \u201cParties,\u201d and each individually as a \u201cParty.\u201d", "id": "3OeLUoDyX3x", "source_url": "https://www.sec.gov/Archives/edgar/data/1527599/000155837016004457/mirn-20151231ex1013fedd7.htm", "category_name": "Patent License Agreement", "company_name": "Mirna Therapeutics, Inc.", "created": "March 30th, 2016", "published": true, "pretty": null, "uri": "/contracts/3OeLUoDyX3x", "title": "PATENT LICENSE AGREEMENT", "group_id": "3OeLUoDyX3x", "group_samples": [{"label": "Patent License Agreement (Mirna Therapeutics, Inc.)", "uri": "/contracts/3OeLUoDyX3x", "published": true}], "group_size": 1, "tags": [{"name": "Patent License Agreement", "type": "category", "uri": "/contracts/tagged/patent-license-agreement"}, {"name": "Mirna Therapeutics, Inc.", "type": "company", "uri": "/company/1527599/mirna-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "", "id": "3XJXhZX5jso", "source_url": "https://www.sec.gov/Archives/edgar/data/1527599/000119312526322160/d91010dex106.htm", "category_name": "Warrant to Purchase Common Stock Amending Agreement", "company_name": "Synlogic, Inc.", "created": "July 29th, 2026", "published": true, "pretty": null, "uri": "/contracts/3XJXhZX5jso", "title": "FORM OF WARRANT TO PURCHASE COMMON STOCK AMENDING AGREEMENT", "group_id": "3XJXhZX5jso", "group_samples": [{"label": "Warrant to Purchase Common Stock Amending Agreement (Synlogic, Inc.)", "uri": "/contracts/3XJXhZX5jso", "published": true}], "group_size": 1, "tags": [{"name": "Warrant to Purchase Common Stock Amending Agreement", "type": "category", "uri": "/contracts/tagged/warrant-to-purchase-common-stock-amending-agreement"}, {"name": "Synlogic, Inc.", "type": "company", "uri": "/company/1527599/synlogic-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "This Agreement, effective as of November 9, 2015 (the \u201cEFFECTIVE DATE\u201d), is between the Massachusetts Institute of Technology (\u201cM.I.T.\u201d), a Massachusetts non-profit corporation, with a principal office at 77 Massachusetts Avenue, Cambridge, MA 02139-4307 and Synlogic, Inc. (\u201cCOMPANY\u201d), a corporation with a principal place of business at 130 Brookline Street, #201, Cambridge, MA 02139. Individually, M.I.T. and COMPANY are a \u201cParty\u201d and collectively, M.I.T. and COMPANY are the \u201cParties\u201d.", "id": "42XzyPW0dpo", "source_url": "https://www.sec.gov/Archives/edgar/data/1527599/000119312517270395/d431294dex1015.htm", "category_name": "Exclusive Patent License Agreement", "company_name": "Synlogic, Inc.", "created": "August 28th, 2017", "published": true, "pretty": null, "uri": "/contracts/42XzyPW0dpo", "title": "MASSACHUSETTS INSTITUTE OF TECHNOLOGY SYNLOGIC, INC. EXCLUSIVE PATENT LICENSE AGREEMENT", "group_id": "42XzyPW0dpo", "group_samples": [{"label": "Exclusive Patent License Agreement (Synlogic, Inc.)", "uri": "/contracts/42XzyPW0dpo", "published": true}], "group_size": 1, "tags": [{"name": "Exclusive Patent License Agreement", "type": "category", "uri": "/contracts/tagged/exclusive-patent-license-agreement"}, {"name": "Synlogic, Inc.", "type": "company", "uri": "/company/1527599/synlogic-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Massachusetts", "type": "jurisdiction", "uri": "/contracts/tagged/massachusetts-us"}]}, {"intro": "In recognition of your value and expected contributions to Synlogic, Inc. (\u201cthe Company\u201d) we are pleased to offer you the following Retention Bonus Agreement (the \u201cAgreement\u201d).", "id": "4AzOtICdP6a", "source_url": "https://www.sec.gov/Archives/edgar/data/1527599/000095017024093282/sybx-ex10_4.htm", "category_name": "Retention Bonus Agreement", "company_name": "Synlogic, Inc.", "created": "August 8th, 2024", "published": true, "pretty": null, "uri": "/contracts/4AzOtICdP6a", "title": "Effective Date: March 1, 2024 Tony Awad Re: Amendment to Retention Bonus Agreement by and between Synlogic, Inc. and Antoine Awad, dated as of March 7, 2024 Dear Tony:", "group_id": "4AzOtICdP6a", "group_samples": [{"label": "Retention Bonus Agreement (Synlogic, Inc.)", "uri": "/contracts/4AzOtICdP6a", "published": true}], "group_size": 1, "tags": [{"name": "Retention Bonus Agreement", "type": "category", "uri": "/contracts/tagged/retention-bonus-agreement"}, {"name": "Synlogic, Inc.", "type": "company", "uri": "/company/1527599/synlogic-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "This Amendment No. 1 (the \u201cAmendment\u201d) effective as of August 1, 2014 (the \u201cAmendment Effective Date\u201d) to the Employment Agreement dated April 18, 2013 (the \u201cAgreement\u201d) is made by and between Mirna Therapeutics, Inc., a Delaware corporation (the \u201cCompany\u201d) and Jon Irvin (\u201cEmployee\u201d).", "id": "4gByQ5PoC3N", "source_url": "https://www.sec.gov/Archives/edgar/data/1527599/000104746915007386/a2226006zex-10_21b.htm", "category_name": "Employment Agreement", "company_name": "Mirna Therapeutics, Inc.", "created": "September 18th, 2015", "published": true, "pretty": null, "uri": "/contracts/4gByQ5PoC3N", "title": "MIRNA THERAPEUTICS LETTERHEAD] AMENDMENT NO. 1 TO THE EMPLOYMENT AGREEMENT", "group_id": "4gByQ5PoC3N", "group_samples": [{"label": "Employment Agreement (Mirna Therapeutics, Inc.)", "uri": "/contracts/4gByQ5PoC3N", "published": true}], "group_size": 1, "tags": [{"name": "Employment Agreement", "type": "category", "uri": "/contracts/tagged/employment-agreement"}, {"name": "Mirna Therapeutics, Inc.", "type": "company", "uri": "/company/1527599/mirna-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "In recognition of your value and expected contributions to Synlogic, Inc. (\u201cthe Company\u201d) we are pleased to offer you the following Retention Bonus Agreement (the \u201cAgreement\u201d).", "id": "4p5TVh8IcSq", "source_url": "https://www.sec.gov/Archives/edgar/data/1527599/000095017024093282/sybx-ex10_6.htm", "category_name": "Retention Bonus Agreement", "company_name": "Synlogic, Inc.", "created": "August 8th, 2024", "published": true, "pretty": null, "uri": "/contracts/4p5TVh8IcSq", "title": "Re: 1st Amendment to the Retention Agreement", "group_id": "4p5TVh8IcSq", "group_samples": [{"label": "Retention Bonus Agreement (Synlogic, Inc.)", "uri": "/contracts/4p5TVh8IcSq", "published": true}], "group_size": 1, "tags": [{"name": "Retention Bonus Agreement", "type": "category", "uri": "/contracts/tagged/retention-bonus-agreement"}, {"name": "Synlogic, Inc.", "type": "company", "uri": "/company/1527599/synlogic-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "The purpose of this letter agreement (\u201cAgreement\u201d) is to confirm the terms of your voluntary separation of employment from Synlogic, Inc. (\u201cSynlogic\u201d or \u201cthe Company\u201d).1The Bonus Pay and Benefits described below are contingent on your agreement to and compliance with the provisions of this Agreement, as set forth below. In order to accept the Bonus Pay and Benefits offered in this Agreement, you must sign and return the same on, or before November 30, 2023. This Agreement shall be effective on the eighth (8th) day after you sign the same (the \u201cEffective Date\u201d).", "id": "4tLmUOuhgfN", "source_url": "https://www.sec.gov/Archives/edgar/data/1527599/000095017024033146/sybx-ex10_18.htm", "category_name": "Separation Agreement", "company_name": "Synlogic, Inc.", "created": "March 19th, 2024", "published": true, "pretty": null, "uri": "/contracts/4tLmUOuhgfN", "title": "Provided on November 9, 2023 Michael Jensen Dear Michael,", "group_id": "4tLmUOuhgfN", "group_samples": [{"label": "Separation Agreement (Synlogic, Inc.)", "uri": "/contracts/4tLmUOuhgfN", "published": true}], "group_size": 1, "tags": [{"name": "Separation Agreement", "type": "category", "uri": "/contracts/tagged/separation-agreement"}, {"name": "Synlogic, Inc.", "type": "company", "uri": "/company/1527599/synlogic-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "The purpose of this letter agreement (the \u201cAgreement\u201d) is to confirm the terms regarding your separation of employment with Synlogic, Inc. (the \u201cCompany\u201d). As more fully set forth below, the Company desires to provide you with certain severance pay and benefits, in exchange for certain agreements by you.", "id": "5IZ4DJSNvDW", "source_url": "https://www.sec.gov/Archives/edgar/data/1527599/000156459019018049/sybx-ex101_109.htm", "category_name": "Separation Agreement", "company_name": "Synlogic, Inc.", "created": "May 9th, 2019", "published": true, "pretty": null, "uri": "/contracts/5IZ4DJSNvDW", "title": "Synlogic, Inc. Cambridge, MA 02142", "group_id": "5IZ4DJSNvDW", "group_samples": [{"label": "Separation Agreement (Synlogic, Inc.)", "uri": "/contracts/5IZ4DJSNvDW", "published": true}], "group_size": 1, "tags": [{"name": "Separation Agreement", "type": "category", "uri": "/contracts/tagged/separation-agreement"}, {"name": "Synlogic, Inc.", "type": "company", "uri": "/company/1527599/synlogic-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Massachusetts", "type": "jurisdiction", "uri": "/contracts/tagged/massachusetts-us"}]}, {"intro": "This Change in Control Severance Agreement (the \u201cAgreement\u201d) is made and entered into by and between [ ] (\u201cExecutive\u201d) and Mirna Therapeutics, Inc. (the \u201cCompany\u201d), effective as of the latest date set forth by the signatures of the parties hereto below (the \u201cEffective Date\u201d).", "id": "5Y3BOqHUdlh", "source_url": "https://www.sec.gov/Archives/edgar/data/1527599/000104746915007251/a2225898zex-10_12.htm", "category_name": "Change in Control Severance Agreement", "company_name": "Mirna Therapeutics, Inc.", "created": "September 11th, 2015", "published": true, "pretty": null, "uri": "/contracts/5Y3BOqHUdlh", "title": "MIRNA THERAPEUTICS, INC. CHANGE IN CONTROL SEVERANCE AGREEMENT", "group_id": "5Y3BOqHUdlh", "group_samples": [{"label": "Change in Control Severance Agreement (Mirna Therapeutics, Inc.)", "uri": "/contracts/5Y3BOqHUdlh", "published": true}], "group_size": 1, "tags": [{"name": "Change in Control Severance Agreement", "type": "category", "uri": "/contracts/tagged/change-in-control-severance-agreement"}, {"name": "Mirna Therapeutics, Inc.", "type": "company", "uri": "/company/1527599/mirna-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Texas", "type": "jurisdiction", "uri": "/contracts/tagged/texas-us"}]}, {"intro": "This amendment no. 1 to the Pilot Collaboration and Option Agreement effective as of 16 June 2021 (the \"Amendment No. 1\") is entered into effective as of 15 August, 2023 (the \"Amendment No. 1 Effective Date\") by and between Hoffmann-La Roche Inc., with an office and place of business at 150 Clove Road, Suite 8, Little Falls, New Jersey 07424, U.S.A. (\"Roche US\") and F. Hoffmann-La Roche Ltd, located at Grenzacherstrasse 124, 4070 Basel, Switzerland (\"Roche Basel\", Roche Basel and Roche US together referred to as \u201cRoche\u201d), on the one hand, and Synlogic Operating Company, Inc., located at 301 Binney St., Suite 402, Cambridge, MA 02142 (hereafter referred to as \u201cSynlogic\u201d), on the other hand.", "id": "5oEINcuoAge", "source_url": "https://www.sec.gov/Archives/edgar/data/1527599/000095017023061493/sybx-ex10_1.htm", "category_name": "Pilot Collaboration and Option Agreement", "company_name": "Synlogic, Inc.", "created": "November 9th, 2023", "published": true, "pretty": null, "uri": "/contracts/5oEINcuoAge", "title": "Amendment No. 1 to Pilot Collaboration and Option Agreement", "group_id": "5oEINcuoAge", "group_samples": [{"label": "Pilot Collaboration and Option Agreement (Synlogic, Inc.)", "uri": "/contracts/5oEINcuoAge", "published": true}], "group_size": 1, "tags": [{"name": "Pilot Collaboration and Option Agreement", "type": "category", "uri": "/contracts/tagged/pilot-collaboration-and-option-agreement"}, {"name": "Synlogic, Inc.", "type": "company", "uri": "/company/1527599/synlogic-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "On behalf of Mirna Therapeutics, Inc. (\u201cMirna\u201d), a Delaware corporation, I am pleased to offer you the full-time position of Chief Financial Officer. We anticipate your start date to be September 8, 2015 (the \u201cStart Date\u201d).", "id": "66wxehruGJl", "source_url": "https://www.sec.gov/Archives/edgar/data/1527599/000104746915007386/a2226006zex-10_20a.htm", "category_name": "Employment Agreement", "company_name": "Mirna Therapeutics, Inc.", "created": "September 18th, 2015", "published": true, "pretty": null, "uri": "/contracts/66wxehruGJl", "title": "MIRNA THERAPEUTICS LETTERHEAD]", "group_id": "66wxehruGJl", "group_samples": [{"label": "Employment Agreement (Mirna Therapeutics, Inc.)", "uri": "/contracts/66wxehruGJl", "published": true}], "group_size": 1, "tags": [{"name": "Employment Agreement", "type": "category", "uri": "/contracts/tagged/employment-agreement"}, {"name": "Mirna Therapeutics, Inc.", "type": "company", "uri": "/company/1527599/mirna-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "performed or services delivered and comply with all federal and state laws regarding the conduct of the research or service.", "id": "6Rty2sFOgbO", "source_url": "https://www.sec.gov/Archives/edgar/data/1527599/000104746915007251/a2225898zex-10_19.htm", "category_name": "Cancer Research Grant Contract", "company_name": "Mirna Therapeutics, Inc.", "created": "September 11th, 2015", "published": true, "pretty": null, "uri": "/contracts/6Rty2sFOgbO", "title": "RECITALS", "group_id": "6Rty2sFOgbO", "group_samples": [{"label": "Cancer Research Grant Contract (Mirna Therapeutics, Inc.)", "uri": "/contracts/6Rty2sFOgbO", "published": true}], "group_size": 1, "tags": [{"name": "Cancer Research Grant Contract", "type": "category", "uri": "/contracts/tagged/cancer-research-grant-contract"}, {"name": "Mirna Therapeutics, Inc.", "type": "company", "uri": "/company/1527599/mirna-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Texas", "type": "jurisdiction", "uri": "/contracts/tagged/texas-us"}]}, {"intro": "THIS FOUNDRY TERMS OF SERVICE AGREEMENT (this \u201cTSA\u201d) is entered into as of June 11, 2019 (the \u201cEffective Date\u201d) by and between Synlogic Operating Company, Inc., a corporation organized under the laws of Delaware (\u201cCustomer\u201d) and Ginkgo Bioworks, Inc., a corporation organized under the laws of Delaware (\u201cGinkgo\u201d). Customer and Ginkgo are sometimes referred to herein individually as a \u201cParty\u201d and collectively as the \u201cParties.\u201d", "id": "6VLMHO8v6Ha", "source_url": "https://www.sec.gov/Archives/edgar/data/1527599/000156459019030838/sybx-ex102_134.htm", "category_name": "Foundry Terms of Service Agreement", "company_name": "Synlogic, Inc.", "created": "August 8th, 2019", "published": true, "pretty": null, "uri": "/contracts/6VLMHO8v6Ha", "title": "FOUNDRY TERMS OF SERVICE AGREEMENT", "group_id": "6VLMHO8v6Ha", "group_samples": [{"label": "Foundry Terms of Service Agreement (Synlogic, Inc.)", "uri": "/contracts/6VLMHO8v6Ha", "published": true}], "group_size": 1, "tags": [{"name": "Foundry Terms of Service Agreement", "type": "category", "uri": "/contracts/tagged/foundry-terms-of-service-agreement"}, {"name": "Synlogic, Inc.", "type": "company", "uri": "/company/1527599/synlogic-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Massachusetts", "type": "jurisdiction", "uri": "/contracts/tagged/massachusetts-us"}]}, {"intro": "This THIRD AMENDMENT TO AGREEMENT AND PLAN OF MERGER and FIRST AMENDMENT TO LICENSE AGREEMENT (this \u201cThird Amendment\u201d), is entered into as of December [ 18 ], 2018 (the \u201cThird Amendment Effective Date\u201d), by and among AbbVie S.A.r.l., a corporation organized under the laws of Luxembourg (\u201cBuyer\u201d), Synlogic IBDCo, Inc., a Delaware corporation (the \u201cCompany\u201d) and Synlogic Operating Company, Inc., a Delaware corporation formerly known as, and as successor to, Synlogic, LLC (the \u201cParent\u201d).", "id": "71MsOInRFZu", "source_url": "https://www.sec.gov/Archives/edgar/data/1527599/000156459019007367/sybx-ex1025_537.htm", "category_name": "Agreement and Plan of Merger", "company_name": "Synlogic, Inc.", "created": "March 12th, 2019", "published": true, "pretty": null, "uri": "/contracts/71MsOInRFZu", "title": "THIRD AMENDMENT TO AGREEMENT AND PLAN OF MERGER FIRST AMENDMENT TO LICENSE AGREEMENT", "group_id": "71MsOInRFZu", "group_samples": [{"label": "Agreement and Plan of Merger (Synlogic, Inc.)", "uri": "/contracts/71MsOInRFZu", "published": true}], "group_size": 1, "tags": [{"name": "Agreement and Plan of Merger", "type": "category", "uri": "/contracts/tagged/agreement-and-plan-of-merger"}, {"name": "Synlogic, Inc.", "type": "company", "uri": "/company/1527599/synlogic-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Delaware", "type": "jurisdiction", "uri": "/contracts/tagged/delaware-us"}]}, {"intro": "THIS STATEMENT OF WORK (the \u201cStatement of Work\u201d) by and between Synlogic Operating Company, Inc. (\u201cSynlogic\u201d) and Azzur Group (d/b/a Azzur of New England LLC) (\u201cService Provider\u201d), will be effective as of the last date of signature below, and upon execution will be incorporated into the Master Contract Services Agreement between Synlogic and Service Provider dated 08 September 2018 (the \u201cAgreement\u201d). Capitalized terms used in this Statement of Work will have the same meaning as set forth in the Agreement.", "id": "7hrh5HvifKq", "source_url": "https://www.sec.gov/Archives/edgar/data/1527599/000156459019007367/sybx-ex1030_620.htm", "category_name": "Statement of Work", "company_name": "Synlogic, Inc.", "created": "March 12th, 2019", "published": true, "pretty": null, "uri": "/contracts/7hrh5HvifKq", "title": "CONFIDENTIAL TREATMENT REQUESTED", "group_id": "7hrh5HvifKq", "group_samples": [{"label": "Statement of Work (Synlogic, Inc.)", "uri": "/contracts/7hrh5HvifKq", "published": true}], "group_size": 1, "tags": [{"name": "Statement of Work", "type": "category", "uri": "/contracts/tagged/statement-of-work"}, {"name": "Synlogic, Inc.", "type": "company", "uri": "/company/1527599/synlogic-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "", "id": "7yO6EH9TsTE", "source_url": "https://www.sec.gov/Archives/edgar/data/1527599/000119312517270395/d431294dex109.htm", "category_name": "Employment Agreement", "company_name": "Synlogic, Inc.", "created": "August 28th, 2017", "published": true, "pretty": null, "uri": "/contracts/7yO6EH9TsTE", "title": "Synlogic, Inc.", "group_id": "7yO6EH9TsTE", "group_samples": [{"label": "Employment Agreement (Synlogic, Inc.)", "uri": "/contracts/7yO6EH9TsTE", "published": true}], "group_size": 1, "tags": [{"name": "Employment Agreement", "type": "category", "uri": "/contracts/tagged/employment-agreement"}, {"name": "Synlogic, Inc.", "type": "company", "uri": "/company/1527599/synlogic-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Massachusetts", "type": "jurisdiction", "uri": "/contracts/tagged/massachusetts-us"}]}, {"intro": "In recognition of your value and expected contributions to Synlogic, Inc. (\u201cthe Company\u201d) we are pleased to offer you the following Retention Bonus Agreement (the \u201cAgreement\u201d).", "id": "84lt1DdX8Vn", "source_url": "https://www.sec.gov/Archives/edgar/data/1527599/000095017024033146/sybx-ex10_23.htm", "category_name": "Retention Bonus Agreement", "company_name": "Synlogic, Inc.", "created": "March 19th, 2024", "published": true, "pretty": null, "uri": "/contracts/84lt1DdX8Vn", "title": "Re: Retention Agreement", "group_id": "84lt1DdX8Vn", "group_samples": [{"label": "Retention Bonus Agreement (Synlogic, Inc.)", "uri": "/contracts/84lt1DdX8Vn", "published": true}], "group_size": 1, "tags": [{"name": "Retention Bonus Agreement", "type": "category", "uri": "/contracts/tagged/retention-bonus-agreement"}, {"name": "Synlogic, Inc.", "type": "company", "uri": "/company/1527599/synlogic-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "This letter confirms our earlier discussions and memorializes the decision approved by the Board of Directors of Synlogic, Inc. (the \u201cCompany\u201d) to amend certain provisions of your employment offer letter, effective as of June 22, 2016, and amended as of November 7, 2016, by and between you and the Company (the \u201cLetter Agreement\u201d). The following amendment to the Letter Agreement will be effective as of May 16, 2017.", "id": "8T32CGR0lix", "source_url": "https://www.sec.gov/Archives/edgar/data/1527599/000119312517270395/d431294dex108.htm", "category_name": "Offer Letter", "company_name": "Synlogic, Inc.", "created": "August 28th, 2017", "published": true, "pretty": null, "uri": "/contracts/8T32CGR0lix", "title": "Synlogic, Inc.", "group_id": "8T32CGR0lix", "group_samples": [{"label": "Offer Letter (Synlogic, Inc.)", "uri": "/contracts/8T32CGR0lix", "published": true}], "group_size": 1, "tags": [{"name": "Offer Letter", "type": "category", "uri": "/contracts/tagged/offer-letter"}, {"name": "Synlogic, Inc.", "type": "company", "uri": "/company/1527599/synlogic-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "This Consulting Agreement (the \u201cAgreement\u201d) is made effective as of October 18, 2019 (the \u201cEffective Date\u201d), by and between Synlogic Operating Company, Inc., a Delaware corporation, with its principal place of business being 301 Binney Street, Suite 402, Cambridge MA 02142 (the \u201cCompany\u201d) and Danforth Advisors, LLC, a Massachusetts limited liability corporation, with its principal place of business being 91 Middle Road, Southborough, MA 01772 (\u201cDanforth\u201d). The Company and Danforth are herein sometimes referred to individually as a \u201cParty\u201d and collectively as the \u201cParties.\u201d", "id": "8qX69VlfeHA", "source_url": "https://www.sec.gov/Archives/edgar/data/1527599/000119312519273622/d820489dex101.htm", "category_name": "Consulting Agreement", "company_name": "Synlogic, Inc.", "created": "October 25th, 2019", "published": true, "pretty": null, "uri": "/contracts/8qX69VlfeHA", "title": "CONSULTING AGREEMENT", "group_id": "8qX69VlfeHA", "group_samples": [{"label": "Consulting Agreement (Synlogic, Inc.)", "uri": "/contracts/8qX69VlfeHA", "published": true}], "group_size": 1, "tags": [{"name": "Consulting Agreement", "type": "category", "uri": "/contracts/tagged/consulting-agreement"}, {"name": "Synlogic, Inc.", "type": "company", "uri": "/company/1527599/synlogic-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Massachusetts", "type": "jurisdiction", "uri": "/contracts/tagged/massachusetts-us"}]}, {"intro": "[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.", "id": "9lgq3yweX5l", "source_url": "https://www.sec.gov/Archives/edgar/data/1527599/000104746915007251/a2225898zex-10_3g.htm", "category_name": "License Agreement", "company_name": "Mirna Therapeutics, Inc.", "created": "September 11th, 2015", "published": true, "pretty": null, "uri": "/contracts/9lgq3yweX5l", "title": "MIRNA THERAPEUTICS LETTERHEAD]", "group_id": "9lgq3yweX5l", "group_samples": [{"label": "License Agreement (Mirna Therapeutics, Inc.)", "uri": "/contracts/9lgq3yweX5l", "published": true}], "group_size": 1, "tags": [{"name": "License Agreement", "type": "category", "uri": "/contracts/tagged/license-agreement"}, {"name": "Mirna Therapeutics, Inc.", "type": "company", "uri": "/company/1527599/mirna-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "Contract Document F: This Attachment (this \u201cAttachment\u201d), dated as of May 11, 2017, is hereby incorporated into and made a part of that certain CANCER RESEARCH GRANT CONTRACT (\u201cContract\u201d) effective as of June 1, 2014 by and between the Cancer Prevention and Research Institute of Texas (\u201cCPRIT\u201d or the \u201cINSTITUTE\u201d) and Mirna Therapeutics, Inc. (the \u201cRECIPIENT\u201d). A capitalized term used in this Attachment shall have the meaning given the term in the Contract or in the Attachments to the Contract, unless otherwise defined herein. In the event of a conflict between the provisions of this Attachment and the provisions of the Contract, this Attachment shall control. 1. Mirna hereby provides notice of its intent to terminate that certain Cancer Research Grant Contract by and between CPRIT and Mirna effective as of June 1, 2014 (including any attachments thereto, the (\u201c2014 Contract\u201d) pursuant to Section 8.04 thereof. The termination of the 2014 Contract will be made prior to the Termination Da", "id": "GXWSEFBpKR", "source_url": "https://www.sec.gov/Archives/edgar/data/1527599/000119312517209493/d390888dex104b.htm", "category_name": "Cancer Research Grant Contract", "company_name": "Mirna Therapeutics, Inc.", "created": "June 21st, 2017", "published": true, "pretty": null, "uri": "/contracts/GXWSEFBpKR", "title": "Grant ID: DP140067 Attachment F - Contract Amendment", "group_id": "GXWSEFBpKR", "group_samples": [{"label": "Cancer Research Grant Contract (Mirna Therapeutics, Inc.)", "uri": "/contracts/GXWSEFBpKR", "published": true}], "group_size": 1, "tags": [{"name": "Cancer Research Grant Contract", "type": "category", "uri": "/contracts/tagged/cancer-research-grant-contract"}, {"name": "Mirna Therapeutics, Inc.", "type": "company", "uri": "/company/1527599/mirna-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "This EMPLOYMENT AGREEMENT (the \u201cAgreement\u201d) is made and entered into this 18th day of April, 2013 (the \u201cEffective Date\u201d) by and between Mirna Therapeutics, Inc., a Delaware corporation (the \u201cCompany\u201d) and Jon Irvin (\u201cEmployee\u201d).", "id": "Z7gk1N8AwX", "source_url": "https://www.sec.gov/Archives/edgar/data/1527599/000104746915007386/a2226006zex-10_21a.htm", "category_name": "Employment Agreement", "company_name": "Mirna Therapeutics, Inc.", "created": "September 18th, 2015", "published": true, "pretty": null, "uri": "/contracts/Z7gk1N8AwX", "title": "MIRNA THERAPEUTICS LETTERHEAD]", "group_id": "Z7gk1N8AwX", "group_samples": [{"label": "Employment Agreement (Mirna Therapeutics, Inc.)", "uri": "/contracts/Z7gk1N8AwX", "published": true}], "group_size": 1, "tags": [{"name": "Employment Agreement", "type": "category", "uri": "/contracts/tagged/employment-agreement"}, {"name": "Mirna Therapeutics, Inc.", "type": "company", "uri": "/company/1527599/mirna-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Texas", "type": "jurisdiction", "uri": "/contracts/tagged/texas-us"}]}, {"intro": "", "id": "aG2XmzkcgTg", "source_url": "https://www.sec.gov/Archives/edgar/data/1527599/000156459021015256/sybx-ex1013_238.htm", "category_name": "Employment Letter Agreement", "company_name": "Synlogic, Inc.", "created": "March 25th, 2021", "published": true, "pretty": null, "uri": "/contracts/aG2XmzkcgTg", "title": "Synlogic, Inc.", "group_id": "aG2XmzkcgTg", "group_samples": [{"label": "Employment Letter Agreement (Synlogic, Inc.)", "uri": "/contracts/aG2XmzkcgTg", "published": true}], "group_size": 1, "tags": [{"name": "Employment Letter Agreement", "type": "category", "uri": "/contracts/tagged/employment-letter-agreement"}, {"name": "Synlogic, Inc.", "type": "company", "uri": "/company/1527599/synlogic-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Massachusetts", "type": "jurisdiction", "uri": "/contracts/tagged/massachusetts-us"}]}, {"intro": "This EMPLOYMENT AGREEMENT (the \u201cAgreement\u201d) is made and entered into this 1st day of March, 2014 (the \u201cEffective Date\u201d) by and between Mirna Therapeutics, Inc., a Delaware corporation (the \u201cCompany\u201d) and Casi DeYoung (\u201cEmployee\u201d).", "id": "aI2bQGVlveG", "source_url": "https://www.sec.gov/Archives/edgar/data/1527599/000104746915007251/a2225898zex-10_18.htm", "category_name": "Employment Agreement", "company_name": "Mirna Therapeutics, Inc.", "created": "September 11th, 2015", "published": true, "pretty": null, "uri": "/contracts/aI2bQGVlveG", "title": "MIRNA THERAPEUTICS LETTERHEAD]", "group_id": "aI2bQGVlveG", "group_samples": [{"label": "Employment Agreement (Mirna Therapeutics, Inc.)", "uri": "/contracts/aI2bQGVlveG", "published": true}], "group_size": 1, "tags": [{"name": "Employment Agreement", "type": "category", "uri": "/contracts/tagged/employment-agreement"}, {"name": "Mirna Therapeutics, Inc.", "type": "company", "uri": "/company/1527599/mirna-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Texas", "type": "jurisdiction", "uri": "/contracts/tagged/texas-us"}]}, {"intro": "This Amendment No. 1 (the \u201cAmendment\u201d) effective as of October 31, 2014 (the \u201cAmendment Effective Date\u201d), to the Services Agreement (the \u201cTSA\u201d) dated January 1, 2013 is made by and between Mirna Therapeutics, Inc. (\u201cMirna Therapeutics\u201d) and Asuragen, Inc. (\u201cAsuragen\u201d).", "id": "aoLhhpoqd3D", "source_url": "https://www.sec.gov/Archives/edgar/data/1527599/000104746915006962/a2225772zex-10_1b.htm", "category_name": "Services Agreement", "company_name": "Mirna Therapeutics, Inc.", "created": "August 24th, 2015", "published": true, "pretty": null, "uri": "/contracts/aoLhhpoqd3D", "title": "AMENDMENT NO.1 TO THE SERVICES AGREEMENT", "group_id": "aoLhhpoqd3D", "group_samples": [{"label": "Services Agreement (Mirna Therapeutics, Inc.)", "uri": "/contracts/aoLhhpoqd3D", "published": true}], "group_size": 1, "tags": [{"name": "Services Agreement", "type": "category", "uri": "/contracts/tagged/services-agreement"}, {"name": "Mirna Therapeutics, Inc.", "type": "company", "uri": "/company/1527599/mirna-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}], "next_curs": "CjEKEAoKZ3JvdXBfc2l6ZRICCAEKGQoIZ3JvdXBfaWQSDRoLYW9MaGhwb3FkM0QYACAB", "cursor": "CjEKEAoKZ3JvdXBfc2l6ZRICCAIKGQoIZ3JvdXBfaWQSDRoLZzdTT1E2alRVWEUYACAB"}}